Korean drugmaker Samsung Biologics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of interest.

SEOUL, May 22 (Reuters) - South Korean drug maker Samsung BioLogics (207940.KS), opens new tab said on Thursday it plans to separate the company into contract manufacturing and development ...

In 2022, Samsung Biologics acquired Biogen’s remaining shares for $2.3 billion. “This split reflects our decision to enhance competitiveness by responding swiftly to global changes and ...

16 for final approval. Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to ...

Shares of Samsung Biologics Co. and its largest holder Samsung C&T Corp. were volatile after the Korean contract drug manufacturer announced a spin-off plan. Investors saw the plan — which will ...

CDMO weighs plan to build a 6th plant The decision to split the businesses comes in response to industry concerns about conflicts of interest between Samsung Biologics—which contracts with many ...

16 for final approval. Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to ...

The stock trading suspension of Samsung BioLogics starting Thursday seemed to wrap up a chapter in the yearslong brawl over alleged accounting fraud, apparently with the defeat of the biotech company.

During the main track presentation, Samsung Biologics' CEO and President John Rim said, "Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in ...

INCHEON, South Korea, Feb. 12, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that it has received ...

Shares in Samsung Biologics rose 7.1 percent the previous day following reports of a possible spinoff and investor optimism about the move. Biologics counts tech giant Samsung Electronics and builder ...

Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to biosimilars. CDMO refers ...